Rational discovery of novel type-III FTF antagonists to competitively suppress TIF-2 coactivation in liver cancer-Reference-Cited by-同舟云学术

Rational discovery of novel type-III FTF antagonists to competitively suppress TIF-2 coactivation in liver cancer

Published:2019-07-04 Issue:4 Volume:39 Page:304-311
ISSN:1079-9893
Container-title:Journal of Receptors and Signal Transduction
language:en
Short-container-title:Journal of Receptors and Signal Transduction

Author:

Xu Linlin¹,Chen Zhongming¹,Shao Keke¹,Wang Yungang¹,Cui Leilei¹,Guo Naizhou¹

Affiliation:

1. Department of Laboratory Medicine, The First People’s Hospital of Yancheng City, the Fourth Affiliated Hospital of Nantong University, Yancheng, China

Publisher

Informa UK Limited

Subject

Cell Biology,Molecular Biology,Biochemistry

Link

https://www.tandfonline.com/doi/pdf/10.1080/10799893.2019.1690513

Reference40 articles.

1. Nuclear receptor liver receptor homologue 1 (LRH-1) regulates pancreatic cancer cell growth and proliferation

2. Liver receptor homolog-1 (LRH-1): a potential therapeutic target for cancer

3. The alpha1-fetoprotein locus is activated by a nuclear receptor of the Drosophila FTZ-F1 family

4. LRH-1 drives hepatocellular carcinoma partially through induction of c-myc and cyclin E1, and suppression of p21

5. Structure-based Discovery of Antagonists of Nuclear Receptor LRH-1

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Rational design of EGFR dimerization-disrupting peptides: A new strategy to combat drug resistance in targeted lung cancer therapy;Biochimie;2020-09

2. Rational molecular targeting of the inter-subunit interaction between human cardiac troponin hcTnC and hcTnI using switch peptide-competitive biogenic medicines;Computational Biology and Chemistry;2020-08